#Canada #Toronto #Webinar #antibody-drug conjugates #Xtalks

Upcoming Webinar on Antibody-Drug Conjugates

Mark your calendars for September 11, 2025, as Xtalks will host an insightful webinar focused on the latest advancements in antibody-drug conjugates (ADCs). ADCs are a cutting-edge treatment paradigm in the fight against cancer, combining the unique targeting capabilities of monoclonal antibodies with the potent cell-killing effects of cytotoxic drugs.

This free webinar will delve into innovative strategies surrounding ADC design, specifically emphasizing site-specific conjugation and the importance of stable linkers. As many industry professionals are aware, optimizing the drug-antibody ratio (DAR) is paramount for enhancing the efficacy of ADCs while minimizing unwanted toxic effects.

One of the standout speakers for this event will be AI Yusaku Nomura, Business Development Officer at Ajinomoto. Nomura will share insights into a novel conjugation method that vastly improves yield and stability, thus eliminating the need for complex and time-consuming purification processes. This innovative approach utilizes Fc affinity peptides to achieve homogeneous ADCs effectively.

Key Learning Points

During this hour-long session, attendees will learn:
1. How site-specific conjugation can enhance therapeutic capabilities of ADCs by ensuring stability.
2. The significance of optimizing linker design to improve drug release profiles within target cells.
3. Data supporting enhanced therapeutic windows for ADCs designed with novel linkers.

An aspect that has historically troubled ADC development has been the management of the therapeutic window, which refers to the specific dose range where the drug can maintain efficacy without causing significant side effects. Traditional linkers, such as the valine-citrulline (VC) linkers, have exhibited issues related to plasma stability and high lipophilicity. The recently updated linker designs proposed in this webinar offer solutions to enhance plasma stability and allow for selective payload release within cancer cells, thereby optimizing therapeutic benefits.

Furthermore, the new technologies discussed are not limited to disease treatment; they are also applicable to the development of next-generation conjugates that include oligonucleotides, proteins, lipid nanoparticles (LNPs), and proteolysis targeting chimeras (PROTACs). These innovations promise to transform therapeutic strategies across various biopharmaceuticals.

Registration Details

Professionals in the fields of pharmaceuticals, biotechnology, and healthcare are encouraged to participate. To register for this exciting opportunity, please visit the webinar page on Xtalks. This session promises to provide valuable insights essential for anyone involved in ADC research or development.

Xtalks is recognized as a leading provider of webinars catering to the life sciences sector, offering diverse content that keeps professionals current with industry shifts and innovations. This event is an excellent opportunity not only to learn about emerging ADC techniques but also to network with peers and industry experts.

Don't miss out on this chance to enhance your understanding of antibody-drug conjugates and their evolving landscape. Join us on September 11 and prepare to expand your knowledge on one of the most promising fronts in cancer therapy.